Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 10/31/2025

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 145 publications

Critical insights on vibegron in overactive bladder: a comprehensive review of efficacy, safety and patient-reported outcomes.

Critical insights on vibegron in overactive bladder: a comprehensive review of efficacy, safety and patient-reported outcomes.

Journal: World journal of urology
Published: September 06, 2025

Prescribing patterns for beta-3 agonists and anticholinergic medications used in treatment of overactive bladder.

Prescribing patterns for beta-3 agonists and anticholinergic medications used in treatment of overactive bladder.

Journal: Urology
Published: September 03, 2025

Comment on: "Vibegron in overactive bladder: a comprehensive review of efficacy, safety and patient-reported outcomes".

Comment on: "Vibegron in overactive bladder: a comprehensive review of efficacy, safety and patient-reported outcomes".

Journal: World journal of urology
Published: August 27, 2025

Letter to the Editor on "Comparative Efficacy and Safety of Mirabegron and Vibegron in Female Patients With Overactive Bladder: A Systematic Review and Meta-analysis of Randomized Controlled Trials".

Letter to the Editor on "Comparative Efficacy and Safety of Mirabegron and Vibegron in Female Patients With Overactive Bladder: A Systematic Review and Meta-analysis of Randomized Controlled Trials".

Journal: Urology
Published: July 17, 2025

Stability and Activity Collaborative Improvement of Carbonyl Reductase Based on the Modification Strategy for Transition Zone of the Flexible and Rigid Regions: An Application for Vibegron Chiral Intermediate Synthesis in High Efficiency.

Stability and Activity Collaborative Improvement of Carbonyl Reductase Based on the Modification Strategy for Transition Zone of the Flexible and Rigid Regions: An Application for Vibegron Chiral Intermediate Synthesis in High Efficiency.

Journal: Journal of agricultural and food chemistry
Published: July 09, 2025

Main pharmacological differences between mirabegron and vibegron for the treatment of overactive bladder.

Main pharmacological differences between mirabegron and vibegron for the treatment of overactive bladder.

Journal: Actas urologicas espanolas
Published: June 09, 2025

Vibegron in overactive bladder: a comprehensive review of efficacy, safety and patient-reported outcomes.

Vibegron in overactive bladder: a comprehensive review of efficacy, safety and patient-reported outcomes.

Journal: World journal of urology
Published: May 23, 2025

Effect of β3-adrenergic receptor agonists on [18F] fluorodeoxyglucose uptake in brown adipose tissues in positron emission tomography images of elderly patients.

Effect of β3-adrenergic receptor agonists on [18F] fluorodeoxyglucose uptake in brown adipose tissues in positron emission tomography images of elderly patients.

Journal: EJNMMI research
Published: May 08, 2025

Clinically Meaningful Improvements With Vibegron in Men With Overactive Bladder and Benign Prostatic Hyperplasia: A Responder Analysis of the Phase 3 COURAGE Trial.

Clinically Meaningful Improvements With Vibegron in Men With Overactive Bladder and Benign Prostatic Hyperplasia: A Responder Analysis of the Phase 3 COURAGE Trial.

Journal: Urology
Published: May 08, 2025

Comparison of the Efficacy of Vibegron and Fesoterodine for Neurogenic Detrusor Overactivity in Individuals With Spinal Cord Lesion: A Single-Center Prospective Randomized Crossover Trial.

Comparison of the Efficacy of Vibegron and Fesoterodine for Neurogenic Detrusor Overactivity in Individuals With Spinal Cord Lesion: A Single-Center Prospective Randomized Crossover Trial.

Journal: Neurourology and urodynamics
Published: March 28, 2025

Suitability of Crushed Vibegron 75 mg Tablets for Enteral Administration.

Suitability of Crushed Vibegron 75 mg Tablets for Enteral Administration.

Journal: The Senior care pharmacist
Published: March 26, 2025

Add-on or switch to vibegron in patients with overactive bladder insufficiently responding to initial 4-week antimuscarinics: a randomised, parallel-group, multicentre trial (ADVISR) protocol.

Add-on or switch to vibegron in patients with overactive bladder insufficiently responding to initial 4-week antimuscarinics: a randomised, parallel-group, multicentre trial (ADVISR) protocol.

Journal: BMJ open
Published: March 25, 2025
Showing 1-12 of 145

Last Updated: 10/31/2025